Schweikert, B., Malmberg, C., Núñez, M., Dilla, T., Sapin, C., & Hartz, S. (2020). Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain. BMJ Open.
Citación estilo ChicagoSchweikert, Bernd, Chiara Malmberg, Mercedes Núñez, Tatiana Dilla, Christophe Sapin, and Susanne Hartz. "Cost-effectiveness Analysis of Ixekizumab Versus Secukinumab in Patients With Psoriatic Arthritis and Concomitant Moderate-to-severe Psoriasis in Spain." BMJ Open 2020.
Cita MLASchweikert, Bernd, et al. "Cost-effectiveness Analysis of Ixekizumab Versus Secukinumab in Patients With Psoriatic Arthritis and Concomitant Moderate-to-severe Psoriasis in Spain." BMJ Open 2020.